Exenatide Versus Glimepiride in Patients With Type 2 Diabetes

PHASE3CompletedINTERVENTIONAL
Enrollment

1,029

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

exenatide

subcutaneous injection (5mcg or 10mcg), twice a day

DRUG

glimepiride

oral tablet (titrated to maximally tolerated dose), once daily

Trial Locations (114)

Unknown

Research Site, Graz

Research Site, Innsbruck

Research Site, Salzburg

Research Site, Vienna

Research Site, Beroun

Research Site, České Budějovice

Research Site, Hradec Králové

Research Site, Liberec

Research Site, Písek

Research Site, Prague

Research Site, Třebíč

Research Site, Helsinki

Research Site, Kuopio

Research Site, Pori

Research Site, Vaasa

Research Site, Alençon

Research Site, Bois-Guillaume

Research Site, Bourg-des-Comptes

Research Site, Broglie

Research Site, Bron

Research Site, Fléville-devant-Nancy

Research Site, Le Creusot

Research Site, Le Mans

Research Site, Loudun

Research Site, Montigny-lès-Metz

Research Site, Nevers

Research Site, Strasbourg

Research Site, Thouars

Research Site, Tours

Research Site, Valréas

Research Site, Vénissieux

Research Site, Vihiers

Research Site, Altona

Research Site, Aschaffenburg

Research Site, Bad Staffelstein

Research Site, Dresden

Research Site, Eisenach

Research Site, Essen

Research Site, Essen Schonnebeck

Research Site, Falkensee

Research Site, Fulda

Research Site, Hamburg

Research Site, Hamburg-Ottmarschen

Research Site, Heidelberg

Research Site, Leipzig

Research Site, Münster

Research Site, Saarbrücken

Research Site, Saint Ingbert

Research Site, Schenklengsfeld

Research Site, Schkeuditz

Research Site, Witten

Research Site, Budapest

Research Site, Gyula

Research Site, Kecskemét

Research Site, Veszprém

Research Site, Zalaegerszeg

Research Site, County Galway

Research Site, County Waterford

Research Site, Dublin

Research Site, Haifa

Research Site, Holon

Research Site, Jerusalem

Research Site, Tel Litwinsky

Research Site, Ancona

Research Site, Arenzano

Research Site, Atri

Research Site, Bergamo

Research Site, Catanzaro

Research Site, Florence

Research Site, Foggia

Research Site, Forlì

Research Site, Genova

Research Site, Grosseto

Research Site, Milan

Research Site, Monserrato (Cagliari)

Research Site, Napoli

Research Site, Palermo

Research Site, Perugia

Research Site, Pescara

Research Site, Pisa

Research Site, Ravenna

Research Site, Roma

Research Site, San Benedetto del Tronto

Research Site, Siena

Research Site, Treviso

Research Site, Verona

Research Site, Celaya

Research Site, Pachuca

Research Site, Mexico City

Research Site, Monterrey

Research Site, Bialystok

Research Site, Bydgoszcz

Research Site, Lublin

Research Site, Szczecin

Research Site, Warsaw

Research Site, Wroclaw

Research Site, Barcelona

Research Site, Madrid

Research Site, Fribourg

Research Site, Geneva

Research Site, Lausanne

Research Site, Lucerne

Research Site, Bath

Research Site, Belfast

Research Site, Brandford on Avon

Research Site, County Antrim

Research Site, Downpatrick

Research Site, Frome

Research Site, Midsomer Norton

Research Site, Omagh

Research Site, Penzance

Research Site, Plymouth

Research Site, Southdown

Research Site, Wiltshire

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

AstraZeneca

INDUSTRY